

# Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) (Subcutaneous)

Document Number: EOCCO-0784

Last Review Date: 12/02/2025

Date of Origin: 02/04/2025

Dates Reviewed: 02/2025, 10/2025, 12/2025

## I. Length of Authorization <sup>Δ 1,43,47,49,50,52-54,65,68,72,73,79,81,82,89,130,131</sup>

- Initial: Prior authorization validity will be provided initially for 6 months, unless otherwise specified.
  - Use in the treatment of Cutaneous Melanoma:
    - Cutaneous Melanoma neoadjuvant therapy as a single agent: Prior authorization validity may be provided for a maximum of 4 doses.
  - Merkel Cell Carcinoma neoadjuvant therapy: Prior authorization validity may be provided for up to a maximum of 2 doses.
  - Gastric, Esophageal and Esophagogastric/Gastroesophageal Junction Cancer postoperative therapy after surgery: Prior authorization validity may be provided for a maximum of 36 weeks (9 doses).
- Renewal: Prior authorization validity may be renewed every 6 months thereafter, unless otherwise specified.
  - Non-Small Cell Lung Cancer neoadjuvant treatment followed by optional adjuvant treatment: Prior authorization validity may be provided for a maximum of 4 neoadjuvant doses and 13 adjuvant doses.
  - Prior authorization validity may NOT be renewed for the following indications:
    - Merkel Cell Carcinoma (neoadjuvant therapy)
    - Cutaneous Melanoma (neoadjuvant therapy)
    - Gastric, Esophageal and Esophagogastric/Gastroesophageal Junction Cancer: Post-operative therapy after surgery
  - Prior authorization validity may be renewed up to a maximum of 1 year of therapy\* for the following:
    - Cutaneous Melanoma (adjuvant therapy single agent)
    - Esophageal and Esophagogastric/Gastroesophageal Junction Cancer (adjuvant therapy following neoadjuvant chemoradiotherapy)

- Urothelial Carcinoma (adjuvant therapy)
- Prior authorization validity may be renewed up to a maximum of 2 years of therapy\* for the following:
  - Cervical Cancer
  - Esophageal and Esophagogastric/Gastroesophageal Junction Cancer [induction, first-line, and subsequent therapy (excluding single agent subsequent therapy for squamous cell carcinoma)]
  - Gastric Cancer (first-line therapy or subsequent therapy)
  - Renal Cell Carcinoma (in combination with cabozantinib)
  - Squamous Cell Skin Cancer
  - Vaginal Cancer
  - Vulvar Cancer
  - Urothelial Carcinoma (first line therapy in combination with gemcitabine and cisplatin, followed by single-agent maintenance therapy)

*\*Note: The maximum number of doses is dependent on the dosing frequency and duration of therapy. Refer to Section V for exact dosage.*

| Dosing Frequency | Maximum length of therapy | Maximum number of doses |
|------------------|---------------------------|-------------------------|
| 2 weeks          | 1 year                    | 26 doses                |
|                  | 2 years                   | 52 doses                |
| 3 weeks          | 2 years                   | 35 doses                |
| 4 weeks          | 1 year                    | 13 doses                |
|                  | 2 years                   | 26 doses                |

## II. Dosing Limits

### Max Units (per dose and over time) [HCPCS Unit]:

- 600 billable units every 4 weeks

## III. Initial Approval Criteria <sup>1</sup>

Prior authorization validity is provided in the following conditions:

- Patient is at least 18 years of age; **AND**

### Universal Criteria

- Patient has not received previous therapy with a programmed death (PD-1/PD-L1)-directed therapy unless otherwise specified <sup>Δ</sup> (Note: Not applicable when used as switch-therapy from intravenous nivolumab); **AND**

- Therapy will not be used concomitantly with intravenous nivolumab; **AND**
- Therapy will not be used concurrently with intravenous chemotherapy agents (*not applicable when used for FDA approved combination therapy indicated with †*); **AND**
- Intravenous nivolumab must be used in the following:
  - Patients <80 kg; **OR**
  - Patients requiring 900 mg/15,000 units dose<sup>α</sup>; **OR**
  - Patients receiving therapy in combination with ipilimumab; **AND**

**Substitution/Switch-Therapy for Intravenous Nivolumab ‡** 2,4-6,19,20,24,25,31,33,34,36-39,41,42,47-49,61,63-65,72,79-81,83,84,90,94-97,130,131

- Used as substitution for OR switch-therapy from intravenous nivolumab; **AND**
  - Patient has previously met criteria for use of intravenous nivolumab [*see Opdivo IV policy – Document Number: IC-0226 or Opdivo IV-E policy Document Number: IC-0541, as applicable*]; **AND**
    - Patient has been receiving treatment with intravenous nivolumab and has shown a beneficial disease response and absence of unacceptable toxicity while on therapy; **OR**
  - Patient currently meets criteria for use of intravenous nivolumab [*see Opdivo IV policy – Document Number: IC-0226 or Opdivo IV-E policy Document Number: IC-0541, as applicable*]; **AND**
- Patient has any of the following indications for treatment (*may not be all inclusive*):
  - Ampullary Adenocarcinoma
  - Anal Carcinoma
  - Urothelial Carcinoma (Bladder Cancer)
  - Adult Central Nervous System (CNS) Cancers
  - Cervical Cancer
  - Colorectal Cancer (CRC)
  - Appendiceal Adenocarcinoma – Colon Cancer
  - Gastric Cancer/Esophageal Cancer/Gastroesophageal Junction (GEJ) Cancer
  - Gestational Trophoblastic Neoplasia
  - Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  - Hepatocellular Carcinoma (HCC)
  - Kaposi Sarcoma
  - Renal Cell Carcinoma (RCC)
  - Cutaneous Melanoma
  - Uveal Melanoma

- Merkel Cell Carcinoma
- Peritoneal or Pleural Mesothelioma (*Note: May also be used for pericardial mesothelioma and tunica vaginalis testis mesothelioma*)
- Non-Small Cell Lung Cancer (NSCLC)
- Small Bowel Adenocarcinoma
- Small Cell Lung Cancer (SCLC)
- Soft Tissue Sarcoma
- Endometrial carcinoma (Uterine Neoplasms)
- Vulvar Cancer
- Thyroid Carcinoma
- Vaginal Cancer
- Squamous Cell Skin Cancer

#### **Urothelial Carcinoma (Bladder Cancer) † 1,2,30,51,62,92**

- Used as a single agent; **AND**  
Used for locally advanced or metastatic disease that progressed during or following platinum-containing chemotherapy\* OR progression with 12 months of neoadjuvant or adjuvant treatment with a platinum-containing regimen; **OR**
  - Used as adjuvant therapy in patients who are at a high risk for disease recurrence\*\* after undergoing surgical resection; **OR**
- Used in combination with cisplatin and gemcitabine; **AND**
  - Used as first line therapy in patients with unresectable or metastatic disease

**te:** 10,51,60,70

– *If patient was progression free for >12 months after platinum therapy, consider re-treatment with platinum-based therapy if the patient is still platinum eligible (see below for cisplatin- or platinum-ineligible comorbidities).*

- *Cisplatin-ineligible comorbidities may include the following: CrCl < 60 mL/min, ECOG PS ≥ 2 or KPS ≤ 70%, hearing loss of ≥ 25 decibels (dB) at two contiguous frequencies, grade ≥ 2 peripheral neuropathy, or NYHA Heart Failure class ≥ 3. Carboplatin may be substituted for cisplatin in the metastatic setting for cisplatin-ineligible patients such as those with a GFR less than 60 mL/min.*
- *Platinum-ineligible comorbidities may include the following: CrCl < 30 mL/min, ECOG PS ≥ 3, grade ≥ 2 peripheral neuropathy, or NYHA Heart Failure class > 3, etc.*

**ote:** 1,62

– *High risk for disease recurrence is defined as:*

- *ypT2-ypT4a or ypN+ for patients who received neoadjuvant platinum-based therapy (excluding urothelial carcinoma of the prostate with stromal invasion); **OR***
- *pT3-pT4a or pN+ for patients who did not receive neoadjuvant platinum-based therapy*

**Colorectal Cancer (CRC) † 1,2,31,32**

- Patient has microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) disease as determined by an FDA-approved or CLIA-compliant test❖; **AND**
- Used as a single agent; **AND**
  - Used for unresectable or metastatic disease following combination treatment with intravenous nivolumab/ipilimumab; **OR**
  - Used as subsequent therapy for metastatic disease that has progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan regimen

**Gastric Cancer/Esophageal Cancer/Gastroesophageal Junction (GEJ) Cancer † 1,2,44,52,56,69**

- Used as a single agent; **AND**
  - Used as adjuvant treatment of completely resected esophageal or GEJ cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).; **OR**
  - Used as subsequent therapy after prior fluoropyrimidine- and platinum-based chemotherapy; **AND**
    - Used for unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC); **OR**
- Used in combination with fluoropyrimidine- and platinum-containing chemotherapy; **AND**
  - Used as first-line therapy; **AND**
  - Tumor expresses PD-L1 (CPS  $\geq 1$ ) as determined by an FDA-approved or CLIA compliant test❖; **AND**
    - Used in patients with unresectable, advanced or metastatic esophageal squamous cell carcinoma (ESCC); **OR**
    - Used for advanced or metastatic gastric, GEJ, or esophageal adenocarcinomas

**Squamous Cell Carcinoma of the Head and Neck (SCCHN) † 1,2,29,78**

- Used as single-agent therapy; **AND**
- Patient has metastatic disease with disease progression on or after platinum-based therapy; **AND**
- Patient does not have disease of the nasopharynx

**Hepatocellular Carcinoma (HCC) † 1,2,21,86,87**

- Used as single agent therapy; **AND**
- Patient has unresectable or metastatic disease; **AND**
  - Used as first-line therapy following combination treatment with intravenous nivolumab/ipilimumab; **OR**

- Used as subsequent therapy after being previously treated with sorafenib and following combination treatment with intravenous nivolumab/ipilimumab

**Renal Cell Carcinoma (RCC) †<sup>1,2,25,26</sup>**

- Used as a single agent; **AND**
  - Used as first line therapy in patients with intermediate or poor risk advanced disease following treatment with intravenous nivolumab/ipilimumab; **OR**
  - Used as subsequent therapy after prior anti-angiogenic therapy; **OR**
- Used in combination with cabozantinib (Cabometyx only); **AND**
  - Used as first-line therapy for advanced disease

**Cutaneous Melanoma †<sup>1,2,15-18,82,93</sup>**

- Used as single agent therapy; **AND**
  - Used as first-line therapy for unresectable or metastatic disease; **OR**
  - Used as subsequent therapy for unresectable or metastatic disease following treatment with intravenous nivolumab/ipilimumab; **OR**
  - Used as adjuvant treatment and patient has stage IIB, stage IIC, stage III or metastatic disease and has undergone complete resection

**Non-Small Cell Lung Cancer (NSCLC) †<sup>1,2,22,23,43,45,46</sup>**

- Used as single-agent therapy; **AND**
  - Used for metastatic disease; **AND**
  - Used as subsequent therapy on or after platinum-based chemotherapy (Note: Patients with EGFR or ALK genomic tumor aberrations should have disease progression on targeted therapies prior to receiving subcutaneous nivolumab); **OR**
- Used in combination with platinum-doublet chemotherapy; **AND**
  - Used as neoadjuvant therapy in patients who have resectable (tumors  $\geq 4$  cm or node positive) disease; **OR**
  - Used as neoadjuvant therapy in resectable disease with the option of continuing to single-agent subcutaneous nivolumab therapy as adjuvant treatment after surgery

❖ If confirmed using an FDA approved assay – <http://www.fda.gov/companiondiagnostics>

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Ⓢ Orphan Drug

## IV. Renewal Criteria <sup>Δ 1,2,4-6,15-42,43,47,49,50,52-54,68,72,73,79,81,82,89</sup>

Prior authorization validity can be renewed based upon the following criteria:

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Duration of authorization has not been exceeded (*refer to Section I*); **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: immune-mediated adverse reactions (e.g., pneumonitis, hepatitis, colitis, endocrinopathies, nephritis/renal dysfunction, rash/dermatitis [including Stevens-Johnson syndrome (SJS), drug rash with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis (TEN)], myocarditis, pericarditis, vasculitis, solid organ transplant rejection, etc.), severe infusion-related reactions, complications of allogeneic hematopoietic stem cell transplantation (HSCT), etc.

### <sup>Δ</sup> Notes:

- Patients responding to therapy who relapse ≥ 6 months after discontinuation due to duration are eligible to re-initiate PD-directed therapy.
- Patients previously presenting with aggressive disease who are exhibiting stable disease on treatment as their best response (or if therapy improved performance status) may be eligible for continued therapy without interruption or discontinuation.
- Patients who complete adjuvant therapy and progress ≥ 6 months after discontinuation are eligible to re-initiate PD-directed therapy for metastatic disease.
- Patients whose tumors, upon re-biopsy, demonstrate a change in actionable mutation (e.g., MSS initial biopsy; MSI-H subsequent biopsy) may be eligible to re-initiate PD-directed therapy and will be evaluated on a case-by-case basis.
- Patients diagnosed with Renal Cell Carcinoma with clear cell histology who have received previous immuno-oncology therapy may be eligible for treatment with nivolumab as subsequent therapy and will be evaluated on a case-by-case basis.

## V. Dosage/Administration <sup>Δ 1,14,19,20,27,28,31-42,48-50,52-54,55,58,59,61,65,67,68,71-87,89,91,93,96,98-119,122-125,128-131</sup>

| Indication           | Dose  |
|----------------------|---|
| Renal Cell Carcinoma | <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks, until disease progression or unacceptable toxicity; <b>OR</b></li> <li>– 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks administered in combination with cabozantinib up to a maximum of 2 years of therapy</li> </ul> |

|   |   |
|---|---|
| Cutaneous Melanoma  | <p><b><u>Unresectable or metastatic disease:</u></b></p> <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks, until disease progression or unacceptable toxicity</li> </ul> <p><b><u>Adjuvant treatment:</u></b></p> <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks until disease recurrence or unacceptable toxicity for up to 1 year</li> </ul> <p><b><u>Neoadjuvant treatment:</u></b></p> <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 14 days for 4 doses</li> </ul>  |
| Uveal Melanoma  | <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks, until disease progression or unacceptable toxicity</li> </ul>   |
| Merkel Cell Carcinoma   | <p><b><u>Neoadjuvant treatment:</u></b></p> <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks (days 1 and 15) for a total of 2 doses</li> </ul> <p><b><u>All other settings:</u></b></p> <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks, until disease progression or unacceptable toxicity</li> </ul>   |
| NSCLC   | <p><b><u>Neoadjuvant treatment: †</u></b></p> <ul style="list-style-type: none"> <li>• <math>\alpha</math>900 mg/15,000 units with platinum-doublet chemotherapy on the same day every 3 weeks for up to 4 cycles</li> </ul> <p><b><u>Adjuvant treatment:</u></b></p> <ul style="list-style-type: none"> <li>– 1,200 mg/20,000 units every 4 weeks after surgery for up to 13 cycles (up to one year) or until disease progression, recurrence, or unacceptable toxicity</li> </ul> <p><b><u>Single agent:</u></b></p> <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks, until disease progression or unacceptable toxicity</li> </ul>   |
| Urothelial Carcinoma  | <p><b><u>Adjuvant treatment:</u></b></p> <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks, until disease recurrence or unacceptable toxicity for up to 1 year</li> </ul> <p><b><u>Disease progression or second-line treatment:</u></b></p> <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks, until disease progression or unacceptable toxicity</li> </ul> <p><b><u>First-line therapy: †</u></b></p> <ul style="list-style-type: none"> <li>– <math>\alpha</math>900 mg/15,000 units every 3 weeks with cisplatin and gemcitabine on the same day for up to 6 cycles, followed by:</li> <li>– 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks, until disease progression or unacceptable toxicity for up to 2 years</li> </ul> |
| Esophageal and Esophagogastric/Gastroesophageal Junction Cancer | <p><b><u>First-line therapy (MSI-H/dMMR adenocarcinoma and squamous cell carcinoma):</u></b></p> <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks, until disease progression or unacceptable toxicity for up to 2 years</li> </ul> <p><b><u>First line therapy (PD-L1 positive disease): †</u></b></p>   |

|                                     |  |
|-------------------------------------|--|
|                                     | <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks in combination with fluoropyrimidine- and platinum-containing chemotherapy every 2 weeks, until disease progression or unacceptable toxicity for up to 2 years</li> <li>– <math>\alpha</math>900 mg/15,000 units every 3 weeks with fluoropyrimidine- and platinum containing chemotherapy every 3 weeks, until disease progression or unacceptable toxicity for up to 2 years</li> </ul> <p><b><u>Subsequent therapy (MSI-H/dMMR adenocarcinoma and squamous cell carcinoma):</u></b></p> <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks, until disease progression or unacceptable toxicity for up to 2 years</li> </ul> <p><b><u>Subsequent therapy (squamous cell carcinoma):</u></b></p> <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks, until disease progression or unacceptable toxicity</li> </ul> <p><b><u>Post-operative therapy (MSI-H/dMMR adenocarcinoma following preoperative therapy with intravenous nivolumab/ipilimumab):</u></b></p> <ul style="list-style-type: none"> <li>– 1,200 mg/20,000 units every 4 weeks for 36 weeks (9 doses)</li> </ul> <p><b><u>Adjuvant therapy following neoadjuvant chemoradiotherapy:</u></b></p> <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks, until disease progression or unacceptable toxicity for up to 1 year</li> </ul> <p><b><u>Induction therapy for relieving dysphagia (MSI-H/dMMR squamous cell carcinoma):</u></b></p> <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks, until disease progression or unacceptable toxicity for up to 2 years</li> </ul> |
| Gastric Cancer                      | <p><b><u>First-line therapy:</u></b></p> <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks, until disease progression or unacceptable toxicity for up to 2 years; <b>OR</b></li> <li>– 600 mg/10,000 units every 2 weeks in combination with fluoropyrimidine- and platinum-containing chemotherapy every 2 weeks, until disease progression or unacceptable toxicity for up to 2 years †.</li> </ul> <p><b><u>Subsequent therapy:</u></b></p> <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks, until disease progression or unacceptable toxicity for up to 2 years</li> </ul> <p><b><u>Post-operative therapy (following preoperative therapy with intravenous nivolumab/ipilimumab):</u></b></p> <ul style="list-style-type: none"> <li>– 1,200 mg/20,000 units every 4 weeks, every 4 weeks for 36 weeks (9 doses)</li> </ul>  |
| Soft Tissue Sarcoma, Kaposi Sarcoma | <ul style="list-style-type: none"> <li>– 1,200 mg/20,000 units every 4 weeks, until disease progression or unacceptable toxicity</li> </ul>  |
| Squamous Cell Skin cancer           | <ul style="list-style-type: none"> <li>– 600 mg/10,000 units every 2 weeks until disease progression or unacceptable toxicity for up to 2 years</li> </ul>   |

|  |  |
|--|--|
| Vulvar Cancer, Vaginal Cancer, & Cervical Cancer | – 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks, until disease progression or unacceptable toxicity for up to 2 years |
| All other indications                            | – 600 mg/10,000 units every 2 weeks or 1,200 mg/20,000 units every 4 weeks, until disease progression or unacceptable toxicity                   |

**Note:**

- <sup>α</sup>The 900 mg/15,000 units dosing is listed in the prescribing information; however, the IV formulation of nivolumab must be used instead to prevent wastage.
- Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) has different dosage and administration instructions than intravenous nivolumab products.
- Opdivo Qvantig is for subcutaneous use only in the abdomen or thigh.
- Opdivo Qvantig is to be administered by a healthcare professional only.
- Opdivo Qvantig is for subcutaneous use only administered over 3-5 minutes.

## VI. Billing Code/Availability Information

HCPCS Code:

- J9289 – Injection, nivolumab, 2 mg and hyaluronidase-nvhy; 1 billable unit = 2 mg

NDC(s):

- Opdivo Qvantig single-dose vial providing 600 mg nivolumab and 10,000 units hyaluronidase per 5 mL (120 mg/ 2,000 units per mL): 00003-6120-xx

## VII. References

1. Opdivo Qvantig [package insert]. Princeton, NJ; Bristol-Myers Squibb, Inc; October 2025. Accessed November 2025.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) nivolumab and hyaluronidase-nvhy. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed September 2025.
3. Scherpereel A, Mazieres J, Greillier L, et al. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial. [Abstract]. J Clin Oncol 2017;35: Abstract LBA 8507.
4. Walocko FM, Scheier BY, Harms PW, et al. Metastatic Merkel cell carcinoma response to nivolumab. J Immunother Cancer. 2016 Nov 15;4:79.
5. Tawbi HA-H, Forsyth PAJ, Algazi AP, et al. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. J Clin Oncol 2017;35(15\_suppl):abstr 9507.

6. Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. *Lancet Oncol*. 2017 Apr;18(4):446-453. Doi: 10.1016/S1470-2045(17)30104-3. Epub 2017 Feb 18.
7. Zhao X, Ivaturi V, Gopalakrishnan M, et al. Abstract CT 101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types. *Cancer Res* July 1 2017 (77) (13 Supplement) CT101; DOI: 10.1158/1538-7445.AM2017-CT101.
8. Zhao X, Suryawanshi M, Hruska M, et al. Assessment of nivolumab benefit-risk profile of a 240 mg flat dose relative to a 3 mg/kg dosing regimen in patients with advanced tumors. *Ann Oncol* 2017; 28:2002-2008.
9. Feng Y, Xiaoning W, Bajaj G, et al. Nivolumab exposure-response analyses of efficacy and safety in previously treated squamous or nonsquamous non-small cell lung cancer. *ClinCa Res* 2017;23(18): 5394-5405.
10. Gupta S, Bellmunt J, Plimack ER, et al. Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC). *J Clin Oncol*. 2022 June 1;40(16\_suppl):4577.
11. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. *N Engl J Med* 2018; 378:2093-2104.
12. Fahrenbruch R, Kintzel P, Bott AM, et al. Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association. *J Oncol Pract*. 2018 Mar;14(3):e130-e136.
13. Hematology/Oncology Pharmacy Association (2019). Intravenous Cancer Drug Waste Issue Brief. Retrieved from [http://www.hoparx.org/images/hopa/advocacy/Issue-Briefs/Drug\\_Waste\\_2019.pdf](http://www.hoparx.org/images/hopa/advocacy/Issue-Briefs/Drug_Waste_2019.pdf)
14. Bach PB, Conti RM, Muller RJ, et al. Overspending driven by oversized single dose vials of cancer drugs. *BMJ*. 2016 Feb 29;352:i788.
15. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*. 2015 Apr;16(4):375-84. Doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.
16. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med*. 2015 Jan 22;372(4):320-30. Doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.
17. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med*. 2015 Jul 2;373(1):23-34. Doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
18. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. *N Engl J Med*. 2017 Nov 9;377(19):1824-1835. Doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.

19. Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. *Cancer*. 2016 Nov 15;122(21):3344-3353. Doi: 10.1002/cncr.30258. Epub 2016 Aug 17.
20. Piulats JM, Cruz-Merino LDL, Garcia MTC, et al. Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962). *J Clin Oncol* 2017; 35 Abstr 9533.
21. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase ½ dose escalation and expansion trial. *Lancet*. 2017 Jun 24;389(10088):2492-2502. Doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
22. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *N Engl J Med*. 2015 Jul 9;373(2):123-35. Doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
23. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *N Engl J Med*. 2015 Oct 22;373(17):1627-39. Doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
24. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase ½ trial. *Lancet Oncol*. 2016 Jul;17(7):883-895. Doi: 10.1016/S1470-2045(16)30098-5. Epub 2016 Jun 4.
25. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2015 Nov 5;373(19):1803-13. Doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
26. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2018 Apr 5;378(14):1277-1290. Doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
27. Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. *J Clin Oncol*. 2018 May 10;36(14):1428-1439. Doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27.
28. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med*. 2015 Jan 22;372(4):311-9. Doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6.
29. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med*. 2016 Nov 10;375(19):1856-1867. Epub 2016 Oct 8.
30. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2017 Mar;18(3):312-322. Doi: 10.1016/S1470-2045(17)30065-7. Epub 2017 Jan 26.
31. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142):

- an open-label, multicentre, phase 2 study. *Lancet Oncol.* 2017 Sep;18(9):1182-1191. Doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19.
32. Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. *J Clin Oncol.* 2018 Mar 10;36(8):773-779. Doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.
  33. Topalian SL, Bhatia S, Hollebecque A, et al. Non-comparative, open-label, multiple cohort, phase ½ study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC). DOI: 10.1158/1538-7445.AM2017-CT074 Published July 2017.
  34. Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. *Lancet Oncol.* 2018 May;19(5):672-681. Doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27.
  35. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Anal Carcinoma. Version 2.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. September 2025.
  36. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Gestational Trophoblastic Neoplasia. Version 3.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed September 2025.
  37. Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. *Lancet Oncol.* 2019 Feb;20(2):239-253. Doi: 10.1016/S1470-2045(18)30765-4. Epub 2019 Jan 16.
  38. Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. *Lancet Respir Med.* 2019 Mar;7(3):260-270. Doi: 10.1016/S2213-2600(18)30420-X. Epub 2019 Jan 16.
  39. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Small Bowel Adenocarcinoma. Version 3.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most

recent and complete version of the Compendium, go online to NCCN.org. Accessed September 2025.

40. Chan TSY, Li J, Loong F, et al. PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety. *Ann Hematol*. 2018 Jan;97(1):193-196. Doi: 10.1007/s00277-017-3127-2. Epub 2017 Sep 6.
41. Goldman JW, Crino L, Vokes EE, et al. Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets). *J Clin Oncol* 34, no. 15\_suppl (May 20, 2016) 9038-9038. DOI: 10.1200/JCO.2016.34.15\_suppl.9038.
42. Gauvain C, Vauleon E, Chouaid C, et al. Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. *Lung Cancer*. 2018 Feb; 116:62-66. Doi: 10.1016/j.lungcan.2017.12.008.
43. Referenced with permission from the NCCN Clinical Practice Guidelines (NCCN Guidelines®) Non-Small Cell Lung Cancer. Version 8.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed September 2025.
44. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2019;20(11):1506-1517. Doi:10.1016/S1470-2045(19)30626-6.
45. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. *N Engl J Med*. 2019;381(21):2020-2031. Doi:10.1056/NEJMoa1910231.
46. Reck M, Ciuleanu T-E, Dols MC, et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA [abstract]. *J Clin Oncol* 2020;38:Abstract 9501-9501.
47. Zalcman G, Peters S, Mansfield AS, et al. Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma. *Journal of Clinical Oncology* 2017 35:15\_suppl, TPS8581-TPS8581
48. Azad NS, Gray RJ, Overman MJ, et al. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. *J Clin Oncol*. 2020 Jan 20;38(3):214-222.
49. Naumann RW, Hollebecque A, Meyer T, et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. *J Clin Oncol*. 2019 Nov 1;37(31):2825-2834.

50. Choueiri TK, Powles T, Burotto M, et al. 696O\_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. Volume 31, SUPPLEMENT 4, S1159, September 01, 2020.
51. Referenced with permission from the NCCN Clinical Practice Guidelines (NCCN Guidelines®) Bladder Cancer. Version 1.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed September 2025.
52. Referenced with permission from the NCCN Clinical Practice Guidelines (NCCN Guidelines®) Esophageal and Esophagogastric Junction Cancers. Version 4.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed September 2025.
53. Referenced with permission from the NCCN Clinical Practice Guidelines (NCCN Guidelines®) Gastric Cancer. Version 3.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed September 2025.
54. Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractor Hodgkin lymphoma. *Blood*. 2018 Mar 15;131 (11):1183-1194.
55. Cole PD, Mauz-Körholz C, Mascarini M, et al. HL-032: Nivolumab and Brentuximab Vedotin (BV)–Based, Response-Adapted Treatment in Children, Adolescents, and Young Adults (CAYA) With Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Primary Analysis of the Standard-Risk Cohort of the Phase 2 CheckMate 744 Study. *Clinical Lymphoma Myeloma and Leukemia*. Volume 20, Supplement 1, September 2020, Pages S245-S246.
56. Moehler M, Shitara K, Garrido M, et al. Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. [abstract]. Presented at the Oral Presentation presented at the ESMO 2020 Annual Meeting; September 19-21, 2020; Virtual Meeting.
57. Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. *N Engl J Med*. 2021 Apr 1;384(13):1191-1203. Doi: 10.1056/NEJMoa2032125.

58. Nivolumab. Micromedex Solutions. Greenwood Village, CO: Truven Health Analytics.  
<http://micromedex.com/>. Updated September 09, 2025. Accessed September 2025.
59. Lenz HJ, Lonardi S, Zagonel V, et al. Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update [abstract]. *Journal of Clinical Oncology* 2019;37:3521-3521.
60. Bellmunt, J, Valderrama BP (2025). Treatment of metastatic urothelial cancer of the bladder and urinary tract. In Lerner SP, Shah S (Eds.), *UptoDate*. Last updated Sep 02, 2025. Accessed September 17, 2025. Available from <https://www.uptodate.com/contents/treatment-of-metastatic-urothelial-cancer-of-the-bladder-and-urinary-tract>.
61. Ready NE, Ott PA, Hellmann MD, et al. Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. *J Thorac Oncol*. 2020 Mar;15(3):426-435. Doi: 10.1016/j.jtho.2019.10.004.
62. Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. *N Engl J Med*. 2021 Jun 3;384(22):2102-2114. Doi: 10.1056/NEJMoa2034442.
63. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Cervical Cancer. Version 4.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed September 2025.
64. Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, 16mmune16zed, phase 3 trial. *Lancet Oncol* 2021; 22:1530.
65. Topalian SL, Bhatia S, Amin A, et al. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. *J Clin Oncol*. 2020;38(22):2476-2487. Doi:10.1200/JCO.20.00201.
66. Forde PM, Spicer J, Lu S et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. *N Engl J Med*. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11. PMID: 35403841; PMCID: PMC9844511.
67. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Mesothelioma: Peritoneal. Version 2.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed September 2025.
68. Scherpereel A, Mazieres J, Greillier L, et al; French Cooperative Thoracic Intergroup. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-

- 1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. *Lancet Oncol.* 2019 Feb;20(2):239-253. Doi: 10.1016/S1470-2045(18)30765-4. Epub 2019 Jan 16. Erratum in: *Lancet Oncol.* 2019 Mar;20(3):e132.
69. Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. *N Engl J Med.* 2022 Feb 3;386(5):449-462. Doi: 10.1056/NEJMoa2111380.
  70. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II—results of EORTC study 30986. *J Clin Oncol.* 2009 Nov 20;27(33):5634-9. Doi: 10.1200/JCO.2008.21.4924. Epub 2009 Sep 28.
  71. Bouffet E, Larouche V, Campbell BB, et al. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. *J Clin Oncol.* 2016 Jul 1;34(19):2206-11.
  72. Schenker M, Burotto M, Richardet M, et al. CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. Oral Presentation presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting; April 8-13, 2022; New Orleans, LA.
  73. Mei MG, Lee HJ, Palmer J, et al. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. *Blood.* 2022 Jun 23;139(25):3605-3616. Doi: 10.1182/blood.2022015423.
  74. Zinzani P, Santoro A, Gritti G, et al. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. *J Clin Oncol.* 2019 Nov 20;37(33):3081-3089. Doi: 10.1200/JCO.19.01492. Epub 2019 Aug 9.
  75. Davis K, Fox E, Merchant M, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial. *The Lancet.* Volume 21, issue 4, p541-550, April 01, 2020  
[https://doi.org/10.1016/S1470-2045\(20\)30023-1](https://doi.org/10.1016/S1470-2045(20)30023-1).
  76. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Pediatric Aggressive Mature B-Cell Lymphomas. Version 2.2024. National Comprehensive Cancer Network, 2024. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed September 2024.
  77. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort,

- single-arm phase 2 trial. *Lancet Oncol.* 2016 Sep;17(9):1283-94. Doi: 10.1016/S1470-2045(16)30167-X.
78. Chung C, Li J, Steuer C, et al. Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. *Clin Cancer Res.* 2022 Jun 1;28(11):2329-2338. Doi: 10.1158/1078-0432.CCR-21-3849.
  79. Zer A, Icht O, Yosef L, et al. Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS). *Annals of Oncology.* Volume 33, Issue 7, July 2022, Pages 720-727. <https://doi.org/10.1016/j.annonc.2022.03.012>.
  80. Pelster MS, Gruschkus SK, Bassett R, et al. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. *J Clin Oncol.* 2021 Feb 20;39(6):599-607. Doi: 10.1200/JCO.20.00605.
  81. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, 18mmune18zed, open-label, phase 3 trial. *Lancet.* 2021 Jan 30;397(10272):375-386. Doi: 10.1016/S0140-6736(20)32714-8.
  82. Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. *Nat Med.* 2018 Nov;24(11):1655-1661. Doi: 10.1038/s41591-018-0198-0.
  83. Glutsch V, Kneitz, Gesierich A, et al. Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma. *Cancer Immunology, Immunotherapy* volume 70, pages2087–2093 (2021)
  84. Wagner M, Othus M, Patel S, et al. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). *J Immunother Cancer.* 2021 Aug;9(8):e002990. Doi: 10.1136/jitc-2021-002990.
  85. Kim S, Wuthrick E, Blakaj D, et al. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomized, open label, phase 2 trial. *The Lancet.* Published: September 11, 2022. Doi:[https://doi.org/10.1016/S0140-6736\(22\)01659-2](https://doi.org/10.1016/S0140-6736(22)01659-2). PlumX Metrics
  86. Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol.* 2022 Jan;23(1):77-90.
  87. Kudo M, Matilla A, Santoro A, et al. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. *J Hepatol.* 2021 Sep;75(3):600-609.
  88. Long GV, Del Vecchio M, Weber J, et al. (2023). Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K). *SKIN The Journal of Cutaneous Medicine*, 7(2), s163. <https://doi.org/10.25251/skin.7.suppl.163>.

89. Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. *Blood*. 2021 Aug 12;138(6):427-438. Doi: 10.1182/blood.2020009178.
90. Dagogo-Jack I, Madison RW, Lennerz JK, et al. Molecular characterization of mesothelioma: Impact of histologic type and site of origin on molecular landscape. *JCO Precis Oncol* 2022;6:e2100422.
91. Referenced with permission from the NCCN Clinical Practice Guidelines (NCCN Guidelines®) Colon Cancer. Version 4.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed September 2025.
92. van der Heijden, MS, Sonpavde G, Powles T, et al; CheckMate 901 Trial Investigators. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. *N Engl J Med*. 2023 Nov 9;389(19):1778-1789. doi: 10.1056/NEJMoa2309863. Epub 2023 Oct 22. PMID: 37870949.
93. Amaria R, Reddy S, Tawbi H, et al. Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma. *Nat Med*. 2018 Nov; 24(11): 1649–1654. Published online 2018 Oct 8. Doi: 10.1038/s41591-018-0197-1
94. Ma, D, Ding X, Shi P, et al Combined targeted therapy and immunotherapy in anaplastic thyroid carcinoma with distant metastasis: A case report
95. Kollipara R, Schneider K, Radovich M, et al. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer. *Oncologist* 2017;22:1149-1151.
96. Referenced with permission from the NCCN Clinical Practice Guidelines (NCCN Guidelines®) Thyroid Carcinoma. Version 1.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed September 2025.
97. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Vaginal Cancer. Version 5.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed September 2025.
98. Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. *Nat Med* 2022;28:1178-1188.

99. Versluis JM, Menzies AM, Sikorska K, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACINneo trials. *Ann Oncol* 2023;34:420-430.
100. Referenced with permission from the NCCN Clinical Practice Guidelines (NCCN Guidelines®) Melanoma: Cutaneous Version 2.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to [NCCN.org](https://www.nccn.org). Accessed September 2025.
101. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Nivolumab + Ipilimumab followed by Nivolumab: Colon Cancer Chemotherapy Order Template, COL68. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to [NCCN.org](https://www.nccn.org). Accessed August 2024.
102. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Nivolumab + Ipilimumab followed by Nivolumab: Rectal Cancer Chemotherapy Order Template, REC80. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to [NCCN.org](https://www.nccn.org). Accessed August 2024.
103. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for mFOLFOX6 (Continuous Infusion Fluorouracil/Leucovorin/OXALIplatin) + Nivolumab: Gastric Cancer Chemotherapy Order Template, GAS95. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to [NCCN.org](https://www.nccn.org). Accessed September 2024.
104. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for CapeOX (Capecitabine/OXALIplatin) + Nivolumab: Gastric Cancer Chemotherapy Order Template, GAS96. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to [NCCN.org](https://www.nccn.org). Accessed September 2024.
105. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Nivolumab + Ipilimumab followed by nivolumab: Ampullary Adenocarcinoma Chemotherapy Order Template, AMP22. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are

trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to [NCCN.org](https://www.nccn.org). Accessed July 2024

106. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Nivolumab: Mesothelioma: Peritoneal Chemotherapy Order Template, MPEM10. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to [NCCN.org](https://www.nccn.org). Accessed September 2024.
107. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Nivolumab + Ipilimumab followed by Nivolumab: Central Nervous System Cancers Chemotherapy Order Template, CNS61. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to [NCCN.org](https://www.nccn.org). Accessed September 2024.
108. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Nivolumab: Central Nervous System Cancers Chemotherapy Order Template, CNS63. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to [NCCN.org](https://www.nccn.org). Accessed September 2024.
109. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Nivolumab + Ipilimumab: Non-Small Cell Lung Cancer Chemotherapy Order Template, NSC97. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to [NCCN.org](https://www.nccn.org). Accessed September 2024.
110. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Nivolumab: T-Cell Lymphomas Chemotherapy Order Template, TCL39. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to [NCCN.org](https://www.nccn.org). Accessed September 2024.
111. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Nivolumab: Small Cell Lung Cancer Chemotherapy Order Template, SCL24. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to [NCCN.org](https://www.nccn.org). Accessed September 2024.

112. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Nivolumab: Endometrial Carcinoma Chemotherapy Order Template, UTE34. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed September 2024.
113. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Nivolumab: Cervical Cancer Chemotherapy Order Template, CRV35. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed September 2024.
114. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Nivolumab: Vulvar Cancer Chemotherapy Order Template, VUL17. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed September 2024.
115. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Nivolumab: Vaginal Cancer Chemotherapy Order Template, VAG34. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed September 2024.
116. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Brentuximab vedotin + Nivolumab: Hodgkin Lymphoma Chemotherapy Order Template, HDL53. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed September 2024.
117. Herrera AF, LeBlanc ML, Castellino SM, et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). *Journal of Clinical Oncology* 2023;41:LBA4-LBA4.
118. Bröckelmann PJ, Buhen I, Meissner J et al. Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial. *J Clin Oncol.* 2023 Feb 20;41(6):1193-1199. doi: 10.1200/JCO.22.02355. Epub 2022 Dec 12. PMID: 36508302.
119. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for AVD (DOXOrubicin/VinBLASTine/Dacarbazine) + Nivolumab: Hodgkin Lymphoma

- Chemotherapy Order Template, HDL75. National Comprehensive Cancer Network, 2024. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed September 2024.
120. Cascone T, Awad MM, Spicer JD, et al. Perioperative Nivolumab in Resectable Lung Cancer. *N Engl J Med*. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926. PMID: 38749033.
  121. Opdivo [package insert]. Princeton, NJ; Bristol-Myers Squibb Company; October 2024. Accessed October 2024.
  122. Referenced with permission from the NCCN Clinical Practice Guidelines (NCCN Guidelines®) Kaposi Sarcoma Version 2.2026. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed September 2025.
  123. Referenced with permission from the NCCN Clinical Practice Guidelines (NCCN Guidelines®) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 3.2025. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed September 2025.
  124. Younes A, Brody J, Carpio C, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. *Lancet Haematol* 2019;6:e67-e78.
  125. Lebbe C, Meyer N, Mortier L, et al. Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)(abstract). *Ann Oncol* 2018;29:LBA47.
  126. Andre T, Elez E, Van Cutsem E, et al; CheckMate 8HW Investigators. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. *N Engl J Med*. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141. PMID: 39602630.
  127. Galle PR, Decaens T, Kudo M, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. *JCO* **42**, LBA4008-LBA4008(2024). [https://doi.org/10.1200/JCO.2024.42.17\\_suppl.LBA4008](https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA4008).
  128. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ipilimumab + Nivolumab: Hepatocellular Carcinoma Chemotherapy Order Template, HEP33. National Comprehensive Cancer Network, 2025. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National

Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed June 2025.

129. Patel SP, Othus M, Chae YK, et al. Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: Adrenocortical carcinoma cohort. *J Immunother Cancer* 2024;12:e009074.
130. Munhoz RR, Nader-Marta G, de Camargo VP, et al. A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma. *Cancer*. 2022;128(24):4223-4231. doi:10.1002/cncr.34463
131. Lang R, Welpner T, Richtig E, et al. Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies. *J Eur Acad Dermatol Venereol*. 2023;37(9):1799-1810. doi:10.1111/jdv.19218
132. Harker-Murray P, Mauz-Korholz C, Leblanc T, et al. Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults. *Blood* 2023;141:2075-2084.
133. Greve P, Beishuizen A, Hagleitner M, et al. Nivolumab plus brentuximab vedotin +/- bendamustine combination therapy: A safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma. *Front Immunol* 2023;14:1229558.

## Appendix A – Non-Quantitative Treatment Limitations (NQTL) Factor Checklist

Non-quantitative treatment limitations (NQTLs) refer to the methods, guidelines, standards of evidence, or other conditions that can restrict how long or to what extent benefits are provided under a health plan. These may include things like utilization review or prior authorization. The utilization management NQTL applies comparably, and not more stringently, to mental health/substance use disorder (MH/SUD) Medical Benefit Prescription Drugs and medical/surgical (M/S) Medical Benefit Prescription Drugs. The table below lists the factors that were considered in designing and applying prior authorization to this drug/drug group, and a summary of the conclusions that Prime’s assessment led to for each.

| Factor                     | Conclusion            |
|----------------------------|-----------------------|
| Indication                 | Yes: Consider for PA  |
| Safety and efficacy        | No: PA not a priority |
| Potential for misuse/abuse | No: PA not a priority |
| Cost of drug               | Yes: Consider for PA  |

## Appendix 1 – Covered Diagnosis Codes

| ICD-10 | ICD-10 Description                       |
|--------|--|
| C00.0  | Malignant neoplasm of external upper lip |
| C00.1  | Malignant neoplasm of external lower lip |

|        |   |
|--------|---|
| C00.2  | Malignant neoplasm of external lip, unspecified                       |
| C00.3  | Malignant neoplasm of upper lip, inner aspect                         |
| C00.4  | Malignant neoplasm of lower lip, inner aspect                         |
| C00.5  | Malignant neoplasm of lip, unspecified, inner aspect                  |
| C00.6  | Malignant neoplasm of commissure of lip, unspecified                  |
| C00.8  | Malignant neoplasm of overlapping sites of lip                        |
| C00.9  | Malignant neoplasm of lip, unspecified                                |
| C01    | Malignant neoplasm of base of tongue                                  |
| C02.0  | Malignant neoplasm of dorsal surface of tongue                        |
| C02.1  | Malignant neoplasm of border of tongue                                |
| C02.2  | Malignant neoplasm of ventral surface of tongue                       |
| C02.3  | Malignant neoplasm of anterior two-thirds of tongue, part unspecified |
| C02.4  | Malignant neoplasm of lingual tonsil                                  |
| C02.8  | Malignant neoplasm of overlapping sites of tongue                     |
| C02.9  | Malignant neoplasm of tongue, unspecified                             |
| C03.0  | Malignant neoplasm of upper gum                                       |
| C03.1  | Malignant neoplasm of lower gum                                       |
| C03.9  | Malignant neoplasm of gum, unspecified                                |
| C04.0  | Malignant neoplasm of anterior floor of mouth                         |
| C04.1  | Malignant neoplasm of lateral floor of mouth                          |
| C04.8  | Malignant neoplasm of overlapping sites of floor of mouth             |
| C04.9  | Malignant neoplasm of floor of mouth, unspecified                     |
| C05.0  | Malignant neoplasm of hard palate                                     |
| C05.1  | Malignant neoplasm of soft palate                                     |
| C05.8  | Malignant neoplasm of overlapping sites of palate                     |
| C05.9  | Malignant neoplasm of palate, unspecified                             |
| C06.0  | Malignant neoplasm of cheek mucosa                                    |
| C06.2  | Malignant neoplasm of retromolar area                                 |
| C06.80 | Malignant neoplasm of overlapping sites of unspecified parts of mouth |
| C06.89 | Malignant neoplasm of overlapping sites of other parts of mouth       |
| C06.9  | Malignant neoplasm of mouth, unspecified                              |
| C09.0  | Malignant neoplasm of tonsillar fossa                                 |
| C09.1  | Malignant neoplasm of tonsillar pillar (anterior) (posterior)         |
| C09.8  | Malignant neoplasm of overlapping sites of tonsil                     |

|       |   |
|-------|---|
| C09.9 | Malignant neoplasm of tonsil, unspecified                               |
| C10.0 | Malignant neoplasm of vallecula   |
| C10.1 | Malignant neoplasm of anterior surface of epiglottis                    |
| C10.2 | Malignant neoplasm of lateral wall of oropharynx                        |
| C10.3 | Malignant neoplasm of posterior wall of oropharynx                      |
| C10.4 | Malignant neoplasm of branchial cleft                                   |
| C10.8 | Malignant neoplasm of overlapping sites of oropharynx                   |
| C10.9 | Malignant neoplasm of oropharynx, unspecified                           |
| C11.0 | Malignant neoplasm of superior wall of nasopharynx                      |
| C11.1 | Malignant neoplasm of posterior wall of nasopharynx                     |
| C11.2 | Malignant neoplasm of lateral wall of nasopharynx                       |
| C11.3 | Malignant neoplasm of anterior wall of nasopharynx                      |
| C11.8 | Malignant neoplasm of overlapping sites of nasopharynx                  |
| C11.9 | Malignant neoplasm of nasopharynx, unspecified                          |
| C12   | Malignant neoplasm of pyriform sinus                                    |
| C13.0 | Malignant neoplasm of postcricoid region                                |
| C13.1 | Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect         |
| C13.2 | Malignant neoplasm of posterior wall of hypopharynx                     |
| C13.8 | Malignant neoplasm of overlapping sites of hypopharynx                  |
| C13.9 | Malignant neoplasm of hypopharynx, unspecified                          |
| C14.0 | Malignant neoplasm of pharynx, unspecified                              |
| C14.2 | Malignant neoplasm of Waldeyer's ring                                   |
| C14.8 | Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx |
| C15.3 | Malignant neoplasm of upper third of esophagus                          |
| C15.4 | Malignant neoplasm of middle third of esophagus                         |
| C15.5 | Malignant neoplasm of lower third of esophagus                          |
| C15.8 | Malignant neoplasm of overlapping sites of esophagus                    |
| C15.9 | Malignant neoplasm of esophagus, unspecified                            |
| C16.0 | Malignant neoplasm of cardia  |
| C16.1 | Malignant neoplasm of fundus of stomach                                 |
| C16.2 | Malignant neoplasm of body of stomach                                   |
| C16.3 | Malignant neoplasm of pyloric antrum                                    |
| C16.4 | Malignant neoplasm of pylorus   |
| C16.5 | Malignant neoplasm of lesser curvature of stomach, unspecified          |

|       |  |
|-------|--|
| C16.6 | Malignant neoplasm of greater curvature of stomach, unspecified        |
| C16.8 | Malignant neoplasm of overlapping sites of stomach                     |
| C16.9 | Malignant neoplasm of stomach, unspecified                             |
| C17.0 | Malignant neoplasm of duodenum   |
| C17.1 | Malignant neoplasm of jejunum  |
| C17.2 | Malignant neoplasm of ileum  |
| C17.3 | Meckel's diverticulum, malignant                                       |
| C17.8 | Malignant neoplasm of overlapping sites of small intestine             |
| C17.9 | Malignant neoplasm of small intestine, unspecified                     |
| C18.0 | Malignant neoplasm of cecum  |
| C18.1 | Malignant neoplasm of appendix   |
| C18.2 | Malignant neoplasm of ascending colon                                  |
| C18.3 | Malignant neoplasm of hepatic flexure                                  |
| C18.4 | Malignant neoplasm of transverse colon                                 |
| C18.5 | Malignant neoplasm of splenic flexure                                  |
| C18.6 | Malignant neoplasm of descending colon                                 |
| C18.7 | Malignant neoplasm of sigmoid colon                                    |
| C18.8 | Malignant neoplasm of overlapping sites of colon                       |
| C18.9 | Malignant neoplasm of colon, unspecified                               |
| C19   | Malignant neoplasm of rectosigmoid junction                            |
| C20   | Malignant neoplasm of rectum   |
| C21.0 | Malignant neoplasm of anus, unspecified                                |
| C21.1 | Malignant neoplasm of anal canal                                       |
| C21.2 | Malignant neoplasm of cloacogenic zone                                 |
| C21.8 | Malignant neoplasm of overlapping sites of rectum, anus and anal canal |
| C22.0 | Liver cell carcinoma   |
| C22.8 | Malignant neoplasm of liver, primary, unspecified as to type           |
| C22.9 | Malignant neoplasm of liver, not specified as primary or secondary     |
| C24.1 | Malignant neoplasm of ampulla of Vater                                 |
| C30.0 | Malignant neoplasm of nasal cavity                                     |
| C31.0 | Malignant neoplasm of maxillary sinus                                  |
| C31.1 | Malignant neoplasm of ethmoidal sinus                                  |
| C32.0 | Malignant neoplasm of glottis  |
| C32.1 | Malignant neoplasm of supraglottis                                     |

|         |  |
|---------|--|
| C32.2   | Malignant neoplasm of subglottis   |
| C32.3   | Malignant neoplasm of laryngeal cartilage                                |
| C32.8   | Malignant neoplasm of overlapping sites of larynx                        |
| C32.9   | Malignant neoplasm of larynx, unspecified                                |
| C33     | Malignant neoplasm of trachea  |
| C34.00  | Malignant neoplasm of unspecified main bronchus                          |
| C34.01  | Malignant neoplasm of right main bronchus                                |
| C34.02  | Malignant neoplasm of left main bronchus                                 |
| C34.10  | Malignant neoplasm of upper lobe, unspecified bronchus or lung           |
| C34.11  | Malignant neoplasm of upper lobe, right bronchus or lung                 |
| C34.12  | Malignant neoplasm of upper lobe, left bronchus or lung                  |
| C34.2   | Malignant neoplasm of middle lobe, bronchus or lung                      |
| C34.30  | Malignant neoplasm of lower lobe, unspecified bronchus or lung           |
| C34.31  | Malignant neoplasm of lower lobe, right bronchus or lung                 |
| C34.32  | Malignant neoplasm of lower lobe, left bronchus or lung                  |
| C34.80  | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81  | Malignant neoplasm of overlapping sites of right bronchus and lung       |
| C34.82  | Malignant neoplasm of overlapping sites of left bronchus and lung        |
| C34.90  | Malignant neoplasm of unspecified part of unspecified bronchus or lung   |
| C34.91  | Malignant neoplasm of unspecified part of right bronchus or lung         |
| C34.92  | Malignant neoplasm of unspecified part of left bronchus or lung          |
| C43.0   | Malignant melanoma of lip  |
| C43.111 | Malignant melanoma of right upper eyelid, including canthus              |
| C43.112 | Malignant melanoma of right lower eyelid, including canthus              |
| C43.121 | Malignant melanoma of left upper eyelid, including canthus               |
| C43.122 | Malignant melanoma of left lower eyelid, including canthus               |
| C43.20  | Malignant melanoma of unspecified ear and external auricular canal       |
| C43.21  | Malignant melanoma of right ear and external auricular canal             |
| C43.22  | Malignant melanoma of left ear and external auricular canal              |
| C43.30  | Malignant melanoma of unspecified part of face                           |
| C43.31  | Malignant melanoma of nose   |
| C43.39  | Malignant melanoma of other parts of face                                |
| C43.4   | Malignant melanoma of scalp and neck                                     |
| C43.51  | Malignant melanoma of anal skin  |

|          |   |
|----------|---|
| C43.52   | Malignant melanoma of skin of breast  |
| C43.59   | Malignant melanoma of other part of trunk                                       |
| C43.60   | Malignant melanoma of unspecified upper limb, including shoulder                |
| C43.61   | Malignant melanoma of right upper limb, including shoulder                      |
| C43.62   | Malignant melanoma of left upper limb, including shoulder                       |
| C43.70   | Malignant melanoma of unspecified lower limb, including hip                     |
| C43.71   | Malignant melanoma of right lower limb, including hip                           |
| C43.72   | Malignant melanoma of left lower limb, including hip                            |
| C43.8    | Malignant melanoma of overlapping sites of skin                                 |
| C43.9    | Malignant melanoma of skin, unspecified   |
| C44.00   | Unspecified malignant neoplasm of skin of lip                                   |
| C44.02   | Squamous cell carcinoma of skin of lip  |
| C44.09   | Other specified malignant neoplasm of skin of lip                               |
| C44.121  | Squamous cell carcinoma of skin of unspecified eyelid, including canthus        |
| C44.1221 | Squamous cell carcinoma of skin of right upper eyelid, including canthus        |
| C44.1222 | Squamous cell carcinoma of skin of right lower eyelid, including canthus        |
| C44.1291 | Squamous cell carcinoma of skin of left upper eyelid, including canthus         |
| C44.1292 | Squamous cell carcinoma of skin of left lower eyelid, including canthus         |
| C44.221  | Squamous cell carcinoma of skin of unspecified ear and external auricular canal |
| C44.222  | Squamous cell carcinoma of skin of right ear and external auricular canal       |
| C44.229  | Squamous cell carcinoma of skin of left ear and external auricular canal        |
| C44.320  | Squamous cell carcinoma of skin of unspecified parts of face                    |
| C44.321  | Squamous cell carcinoma of skin of nose   |
| C44.329  | Squamous cell carcinoma of skin of other parts of face                          |
| C44.42   | Squamous cell carcinoma of skin of scalp and neck                               |
| C44.520  | Squamous cell carcinoma of anal skin  |
| C44.521  | Squamous cell carcinoma of skin of breast                                       |
| C44.529  | Squamous cell carcinoma of skin of other part of trunk                          |
| C44.621  | Squamous cell carcinoma of skin of unspecified upper limb, including shoulder   |
| C44.622  | Squamous cell carcinoma of skin of right upper limb, including shoulder         |
| C44.629  | Squamous cell carcinoma of skin of left upper limb, including shoulder          |
| C44.721  | Squamous cell carcinoma of skin of unspecified lower limb, including hip        |
| C44.722  | Squamous cell carcinoma of skin of right lower limb, including hip              |
| C44.729  | Squamous cell carcinoma of skin of left lower limb, including hip               |

|        |   |
|--------|---|
| C44.82 | Squamous cell carcinoma of overlapping sites of skin                                      |
| C44.92 | Squamous cell carcinoma of skin, unspecified  |
| C45.0  | Mesothelioma of pleura  |
| C45.1  | Mesothelioma of peritoneum  |
| C45.2  | Mesothelioma of pericardium   |
| C45.7  | Mesothelioma of other sites   |
| C45.9  | Mesothelioma, unspecified   |
| C46.0  | Kaposi's sarcoma of skin  |
| C46.1  | Kaposi's sarcoma of soft tissue   |
| C46.2  | Kaposi's sarcoma of palate  |
| C46.3  | Kaposi's sarcoma of lymph nodes   |
| C46.4  | Kaposi's sarcoma of gastrointestinal sites  |
| C46.50 | Kaposi's sarcoma of unspecified lung  |
| C46.51 | Kaposi's sarcoma of right lung  |
| C46.52 | Kaposi's sarcoma of left lung   |
| C46.7  | Kaposi's sarcoma of other sites   |
| C46.9  | Kaposi's sarcoma, unspecified   |
| C47.0  | Malignant neoplasm of peripheral nerves of head, face and neck                            |
| C47.10 | Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder     |
| C47.11 | Malignant neoplasm of peripheral nerves of right upper limb, including shoulder           |
| C47.12 | Malignant neoplasm of peripheral nerves of left upper limb, including shoulder            |
| C47.20 | Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip          |
| C47.21 | Malignant neoplasm of peripheral nerves of right lower limb, including hip                |
| C47.22 | Malignant neoplasm of peripheral nerves of left lower limb, including hip                 |
| C47.3  | Malignant neoplasm of peripheral nerves of thorax   |
| C47.4  | Malignant neoplasm of peripheral nerves of abdomen  |
| C47.5  | Malignant neoplasm of peripheral nerves of pelvis   |
| C47.6  | Malignant neoplasm of peripheral nerves of trunk, unspecified                             |
| C47.8  | Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system |
| C47.9  | Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified         |
| C48.0  | Malignant neoplasm of retroperitoneum   |
| C48.1  | Malignant neoplasm of specified parts of peritoneum                                       |
| C48.2  | Malignant neoplasm of peritoneum, unspecified   |
| C48.8  | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum                 |

|         |  |
|---------|--|
| C49.0   | Malignant neoplasm of connective and soft tissue of head, face and neck                        |
| C49.10  | Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder |
| C49.11  | Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder       |
| C49.12  | Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder        |
| C49.20  | Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip      |
| C49.21  | Malignant neoplasm of connective and soft tissue of right lower limb, including hip            |
| C49.22  | Malignant neoplasm of connective and soft tissue of left lower limb, including hip             |
| C49.3   | Malignant neoplasm of connective and soft tissue of thorax                                     |
| C49.4   | Malignant neoplasm of connective and soft tissue of abdomen                                    |
| C49.5   | Malignant neoplasm of connective and soft tissue of pelvis                                     |
| C49.6   | Malignant neoplasm of connective and soft tissue of trunk, unspecified                         |
| C49.8   | Malignant neoplasm of overlapping sites of connective and soft tissue                          |
| C49.9   | Malignant neoplasm of connective and soft tissue, unspecified                                  |
| C4A.0   | Merkel cell carcinoma of lip   |
| C4A.10  | Merkel cell carcinoma of eyelid, including canthus   |
| C4A.111 | Merkel cell carcinoma of right upper eyelid, including canthus                                 |
| C4A.112 | Merkel cell carcinoma of right lower eyelid, including canthus                                 |
| C4A.121 | Merkel cell carcinoma of left upper eyelid, including canthus                                  |
| C4A.122 | Merkel cell carcinoma of left lower eyelid, including canthus                                  |
| C4A.20  | Merkel cell carcinoma of unspecified ear and external auricular canal                          |
| C4A.21  | Merkel cell carcinoma of right ear and external auricular canal                                |
| C4A.22  | Merkel cell carcinoma of left ear and external auricular canal                                 |
| C4A.30  | Merkel cell carcinoma of unspecified part of face  |
| C4A.31  | Merkel cell carcinoma of nose  |
| C4A.39  | Merkel cell carcinoma of other parts of face   |
| C4A.4   | Merkel cell carcinoma of scalp and neck  |
| C4A.51  | Merkel cell carcinoma of anal skin   |
| C4A.52  | Merkel cell carcinoma of skin of breast  |
| C4A.59  | Merkel cell carcinoma of other part of trunk   |
| C4A.60  | Merkel cell carcinoma of unspecified upper limb, including shoulder                            |
| C4A.61  | Merkel cell carcinoma of right upper limb, including shoulder                                  |
| C4A.62  | Merkel cell carcinoma of left upper limb, including shoulder                                   |
| C4A.70  | Merkel cell carcinoma of unspecified lower limb, including hip                                 |
| C4A.71  | Merkel cell carcinoma of right lower limb, including hip                                       |

|        |   |
|--------|---|
| C4A.72 | Merkel cell carcinoma of left lower limb, including hip       |
| C4A.8  | Merkel cell carcinoma of overlapping sites                    |
| C4A.9  | Merkel cell carcinoma, unspecified                            |
| C51.0  | Malignant neoplasm of labium majus                            |
| C51.1  | Malignant neoplasm of labium minus                            |
| C51.2  | Malignant neoplasm of clitoris                                |
| C51.8  | Malignant neoplasm of overlapping sites of vulva              |
| C51.9  | Malignant neoplasm of vulva, unspecified                      |
| C52    | Malignant neoplasm of vagina                                  |
| C53.0  | Malignant neoplasm of endocervix                              |
| C53.1  | Malignant neoplasm of exocervix                               |
| C53.8  | Malignant neoplasm of overlapping sites of cervix uteri       |
| C53.9  | Malignant neoplasm of cervix uteri, unspecified               |
| C54.0  | Malignant neoplasm of isthmus uteri                           |
| C54.1  | Malignant neoplasm of endometrium                             |
| C54.2  | Malignant neoplasm of myometrium                              |
| C54.3  | Malignant neoplasm of fundus uteri                            |
| C54.8  | Malignant neoplasm of overlapping sites of corpus uteri       |
| C54.9  | Malignant neoplasm of corpus uteri, unspecified               |
| C55    | Malignant neoplasm of uterus, part unspecified                |
| C58    | Malignant neoplasm of placenta                                |
| C61    | Malignant neoplasm of prostate                                |
| C64.1  | Malignant neoplasm of right kidney, except renal pelvis       |
| C64.2  | Malignant neoplasm of left kidney, except renal pelvis        |
| C64.9  | Malignant neoplasm of unspecified kidney, except renal pelvis |
| C65.1  | Malignant neoplasm of right renal pelvis                      |
| C65.2  | Malignant neoplasm of left renal pelvis                       |
| C65.9  | Malignant neoplasm of unspecified renal pelvis                |
| C66.1  | Malignant neoplasm of right ureter                            |
| C66.2  | Malignant neoplasm of left ureter                             |
| C66.9  | Malignant neoplasm of unspecified ureter                      |
| C67.0  | Malignant neoplasm of trigone of bladder                      |
| C67.1  | Malignant neoplasm of dome of bladder                         |
| C67.2  | Malignant neoplasm of lateral wall of bladder                 |

|        |  |
|--------|--|
| C67.3  | Malignant neoplasm of anterior wall of bladder                                     |
| C67.4  | Malignant neoplasm of posterior wall of bladder                                    |
| C67.5  | Malignant neoplasm of bladder neck   |
| C67.6  | Malignant neoplasm of ureteric orifice   |
| C67.7  | Malignant neoplasm of urachus  |
| C67.8  | Malignant neoplasm of overlapping sites of bladder                                 |
| C67.9  | Malignant neoplasm of bladder, unspecified   |
| C68.0  | Malignant neoplasm of urethra  |
| C69.30 | Malignant neoplasm of unspecified choroid  |
| C69.31 | Malignant neoplasm of right choroid  |
| C69.32 | Malignant neoplasm of left choroid   |
| C69.40 | Malignant neoplasm of unspecified ciliary body                                     |
| C69.41 | Malignant neoplasm of right ciliary body   |
| C69.42 | Malignant neoplasm of left ciliary body  |
| C69.60 | Malignant neoplasm of unspecified orbit  |
| C69.61 | Malignant neoplasm of right orbit  |
| C69.62 | Malignant neoplasm of left orbit   |
| C73    | Malignant neoplasm of thyroid gland  |
| C76.0  | Malignant neoplasm of head, face and neck  |
| C77.0  | Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck |
| C78.00 | Secondary malignant neoplasm of unspecified lung                                   |
| C78.01 | Secondary malignant neoplasm of right lung   |
| C78.02 | Secondary malignant neoplasm of left lung  |
| C78.6  | Secondary malignant neoplasm of retroperitoneum and peritoneum                     |
| C78.7  | Secondary malignant neoplasm of liver and intrahepatic bile duct                   |
| C79.31 | Secondary malignant neoplasm of brain  |
| C79.89 | Secondary malignant neoplasm of other specified sites                              |
| C7A.1  | Malignant poorly differentiated neuroendocrine tumors                              |
| C7B.1  | Secondary Merkel cell carcinoma  |
| D09.0  | Carcinoma in situ of bladder   |
| D37.01 | Neoplasm of uncertain behavior of lip  |
| D37.02 | Neoplasm of uncertain behavior of tongue   |
| D37.05 | Neoplasm of uncertain behavior of pharynx  |
| D37.09 | Neoplasm of uncertain behavior of other specified sites of the oral cavity         |

|         |   |
|---------|---|
| D37.1   | Neoplasm of uncertain behavior of stomach                             |
| D37.8   | Neoplasm of uncertain behavior of other specified digestive organs    |
| D37.9   | Neoplasm of uncertain behavior of digestive organ, unspecified        |
| D38.0   | Neoplasm of uncertain behavior of larynx                              |
| D38.5   | Neoplasm of uncertain behavior of other respiratory organs            |
| D38.6   | Neoplasm of uncertain behavior of respiratory organ, unspecified      |
| D39.2   | Neoplasm of uncertain behavior of placenta                            |
| O01.9   | Hydatidiform mole, unspecified  |
| Z85.00  | Personal history of malignant neoplasm of unspecified digestive organ |
| Z85.01  | Personal history of malignant neoplasm of esophagus                   |
| Z85.028 | Personal history of other malignant neoplasm of stomach               |
| Z85.068 | Personal history of other malignant neoplasm of small intestine       |
| Z85.09  | Personal history of malignant neoplasm of other digestive organs      |
| Z85.118 | Personal history of other malignant neoplasm of bronchus and lung     |
| Z85.12  | Personal history of malignant neoplasm of trachea                     |
| Z85.42  | Personal history of malignant neoplasm of other parts of uterus       |
| Z85.51  | Personal history of malignant neoplasm of bladder                     |
| Z85.59  | Personal history of malignant neoplasm of other urinary tract organ   |
| Z85.820 | Personal history of malignant melanoma of skin                        |
| Z85.821 | Personal history of Merkel cell carcinoma                             |
| Z85.831 | Personal history of malignant neoplasm of soft tissue                 |

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

| Medicare Part B Administrative Contractor (MAC) Jurisdictions |  |                                    |
|---|--|------------------------------------|
| Jurisdiction  | Applicable State/US Territory          | Contractor                         |
| E (1)   | CA, HI, NV, AS, GU, CNMI               | Noridian Healthcare Solutions, LLC |
| F (2 & 3)   | AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ | Noridian Healthcare Solutions, LLC |

| Medicare Part B Administrative Contractor (MAC) Jurisdictions |   |   |
|---|---|---|
| Jurisdiction  | Applicable State/US Territory   | Contractor  |
| 5   | KS, NE, IA, MO  | Wisconsin Physicians Service Insurance Corp (WPS) |
| 6   | MN, WI, IL  | National Government Services, Inc. (NGS)          |
| H (4 & 7)   | LA, AR, MS, TX, OK, CO, NM  | Novitas Solutions, Inc.                           |
| 8   | MI, IN  | Wisconsin Physicians Service Insurance Corp (WPS) |
| N (9)   | FL, PR, VI  | First Coast Service Options, Inc.                 |
| J (10)  | TN, GA, AL  | Palmetto GBA                                      |
| M (11)  | NC, SC, WV, VA (excluding below)  | Palmetto GBA                                      |
| L (12)  | DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA) | Novitas Solutions, Inc.                           |
| K (13 & 14)   | NY, CT, MA, RI, VT, ME, NH  | National Government Services, Inc. (NGS)          |
| 15  | KY, OH  | CGS Administrators, LLC                           |